Strand Therapeutics started dosing first patients with STX-003, a systemic programmable mRNA therapy designed for tumor-selective activation. The company’s early clinical update emphasizes localized expression as the strategy to avoid systemic toxicity, a core challenge for mRNA approaches that circulate throughout the body. STX-003 reflects Strand’s broader platform direction—using control mechanisms to restrict where the payload is produced after systemic delivery. The first-in-patient dosing marks a new milestone for the program as it moves from preclinical development into human safety and activity evaluation. The trial start adds another entry point for investors tracking whether the company can translate tumor-targeting selectivity into measurable tolerability and early efficacy signals.